Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests th...

Full description

Saved in:
Bibliographic Details
Published inHealth technology assessment (Winchester, England) Vol. 16; no. 35; p. 1
Main Authors Savović, J, Jones, HE, Altman, DG, Harris, RJ, Jűni, P, Pildal, J, Als-Nielsen, B, Balk, EM, Gluud, C, Gluud, LL, Ioannidis, JPA, Schulz, KF, Beynon, R, Welton, N, Wood, L, Moher, D, Deeks, JJ, Sterne, JAC
Format Journal Article
LanguageEnglish
Published England NIHR Journals Library 01.09.2012
Subjects
Online AccessGet full text
ISSN1366-5278
2046-4924
2046-4924
DOI10.3310/hta16350

Cover

Loading…
Abstract The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent. To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure. Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity. The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment. Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias. National Institute for Health Research Health Technology Assessment programme.
AbstractList The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent.BACKGROUNDThe design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent.To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure.OBJECTIVESTo examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure.Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity.DATA SOURCES AND METHODSData were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity.The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment.RESULTSThe analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment.Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias.CONCLUSIONSBias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias.National Institute for Health Research Health Technology Assessment programme.FUNDINGNational Institute for Health Research Health Technology Assessment programme.
The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent. To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure. Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity. The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment. Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias. National Institute for Health Research Health Technology Assessment programme.
Background: The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent. Objectives: To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure. Data sources and methods: Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity. Results: The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment. Conclusions: Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias. Funding: National Institute for Health Research Health Technology Assessment programme.
Author Sterne, JAC
Gluud, C
Schulz, KF
Jűni, P
Jones, HE
Altman, DG
Moher, D
Pildal, J
Beynon, R
Harris, RJ
Balk, EM
Ioannidis, JPA
Als-Nielsen, B
Wood, L
Deeks, JJ
Gluud, LL
Savović, J
Welton, N
Author_xml – sequence: 1
  givenname: J
  surname: Savović
  fullname: Savović, J
  organization: School of Social and Community Medicine, University of Bristol, Bristol, UK
– sequence: 2
  givenname: HE
  surname: Jones
  fullname: Jones, HE
– sequence: 3
  givenname: DG
  surname: Altman
  fullname: Altman, DG
– sequence: 4
  givenname: RJ
  surname: Harris
  fullname: Harris, RJ
– sequence: 5
  givenname: P
  surname: Jűni
  fullname: Jűni, P
– sequence: 6
  givenname: J
  surname: Pildal
  fullname: Pildal, J
– sequence: 7
  givenname: B
  surname: Als-Nielsen
  fullname: Als-Nielsen, B
– sequence: 8
  givenname: EM
  surname: Balk
  fullname: Balk, EM
– sequence: 9
  givenname: C
  surname: Gluud
  fullname: Gluud, C
– sequence: 10
  givenname: LL
  surname: Gluud
  fullname: Gluud, LL
– sequence: 11
  givenname: JPA
  surname: Ioannidis
  fullname: Ioannidis, JPA
– sequence: 12
  givenname: KF
  surname: Schulz
  fullname: Schulz, KF
– sequence: 13
  givenname: R
  surname: Beynon
  fullname: Beynon, R
– sequence: 14
  givenname: N
  surname: Welton
  fullname: Welton, N
– sequence: 15
  givenname: L
  surname: Wood
  fullname: Wood, L
– sequence: 16
  givenname: D
  surname: Moher
  fullname: Moher, D
– sequence: 17
  givenname: JJ
  surname: Deeks
  fullname: Deeks, JJ
– sequence: 18
  givenname: JAC
  surname: Sterne
  fullname: Sterne, JAC
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22989478$$D View this record in MEDLINE/PubMed
BookMark eNplUsluFDEQtVAQWUDiC1AfuXTw1m43NxSxjBSJC5xb1XZ54shtD7YHaf4on4knGxKc7Hp-9ar8qs7JSUwRCXnL6KUQjH64qcCUGOgLcsapVL2cuDwhZ0wo1Q981KfkvJRbSiVTA3tFTjmf9CRHfUbuNtGFPUaDXXJdxl3KFW1X6t4eOovFb2NnbiCDqZh9qd6ULsXOxxb-xlh9C9A5NLXD9rpCxdK5nNYuQ7Rp9aWpmRRrTiG0a80eQvnYoHXxsQEQIRyKL8fyK1bocectrj6FtPUGwn0rHstr8tK1THzzeF6Qn18-_7j61l9__7q5-nTdG6FF7aUdlWpewKLRKjmNODGnF80mOhk1wLSoxdlJgwYQTlNnuGOCDuOgpFCOiwuyedC1CW7nXW5fyoc5gZ_vgZS3M-RmQ8CZWsOtgwWbiBwlhRYI5hbrpDALX5rW-wetXU6_9s2fuflhMASImPZlZm0ggg-aj4367pG6X1a0z4WfJvVXy-RUSkb3TGF0Pi7B_LQEjXr5D9X4CsdR1Qw-_J_wB6mguUE
CitedBy_id crossref_primary_10_1002_14651858_CD011736_pub2
crossref_primary_10_2522_ptj_20140480
crossref_primary_10_1002_14651858_CD005440_pub3
crossref_primary_10_1002_14651858_CD014216
crossref_primary_10_1080_01443615_2020_1820461
crossref_primary_10_1002_14651858_CD006935_pub2
crossref_primary_10_1002_14651858_CD013121
crossref_primary_10_1002_14651858_CD013120
crossref_primary_10_1002_14651858_CD013361
crossref_primary_10_2341_17_060_L
crossref_primary_10_1002_14651858_CD013125
crossref_primary_10_1002_14651858_CD013123
crossref_primary_10_1002_14651858_CD013122
crossref_primary_10_1002_14651858_CD010488_pub2
crossref_primary_10_1371_journal_pmed_1004215
crossref_primary_10_1002_14651858_CD004260_pub3
crossref_primary_10_1111_jep_13019
crossref_primary_10_1371_journal_pone_0128061
crossref_primary_10_20960_angiologia_00700
crossref_primary_10_1097_PR9_0000000000000854
crossref_primary_10_1002_14651858_CD011640_pub2
crossref_primary_10_2217_cer_2019_0201
crossref_primary_10_1002_14651858_MR000050_pub2
crossref_primary_10_1136_bmj_l4697
crossref_primary_10_1177_1941738121998712
crossref_primary_10_1002_14651858_CD012168
crossref_primary_10_1002_jbmr_2036
crossref_primary_10_1002_14651858_CD003046_pub3
crossref_primary_10_1111_cid_12114
crossref_primary_10_1111_bcp_13350
crossref_primary_10_1002_14651858_CD013107
crossref_primary_10_12968_jowc_2020_29_2_79
crossref_primary_10_1002_14651858_CD009060_pub2
crossref_primary_10_1002_14651858_CD012138
crossref_primary_10_1002_14651858_CD013106
crossref_primary_10_1002_14651858_CD011647_pub2
crossref_primary_10_1002_14651858_CD013103_pub2
crossref_primary_10_1002_14651858_CD009918_pub2
crossref_primary_10_1002_14651858_CD003328_pub3
crossref_primary_10_1002_14651858_CD013103
crossref_primary_10_1016_j_mayocpiqo_2023_04_010
crossref_primary_10_1002_14651858_CD012496
crossref_primary_10_1002_14651858_CD012495
crossref_primary_10_1002_14651858_CD007196_pub3
crossref_primary_10_1002_14651858_CD013204_pub2
crossref_primary_10_1002_14651858_CD013120_pub2
crossref_primary_10_1016_j_jclinepi_2024_111644
crossref_primary_10_1038_s41416_020_0761_6
crossref_primary_10_1002_14651858_CD013532_pub2
crossref_primary_10_1002_14651858_CD006745_pub3
crossref_primary_10_1002_14651858_CD011644_pub3
crossref_primary_10_1002_14651858_CD011644_pub2
crossref_primary_10_1002_14651858_CD013471
crossref_primary_10_1002_14651858_CD008545_pub2
crossref_primary_10_1111_nmo_12289
crossref_primary_10_1002_14651858_CD009059_pub2
crossref_primary_10_1002_14651858_CD010872_pub2
crossref_primary_10_1002_14651858_CD005642_pub3
crossref_primary_10_1186_s13643_017_0470_2
crossref_primary_10_1016_j_cct_2015_07_019
crossref_primary_10_1002_14651858_CD010479_pub2
crossref_primary_10_1002_14651858_CD012359
crossref_primary_10_1002_14651858_CD012608_pub2
crossref_primary_10_1002_14651858_CD012358
crossref_primary_10_1002_14651858_CD012608_pub3
crossref_primary_10_1002_14651858_CD013204
crossref_primary_10_1080_09638237_2016_1244716
crossref_primary_10_1002_14651858_CD011026
crossref_primary_10_1002_14651858_CD013203
crossref_primary_10_1002_14651858_CD007470_pub3
crossref_primary_10_1080_08870446_2014_953531
crossref_primary_10_1289_ehp_1510532
crossref_primary_10_1002_ebch_1985
crossref_primary_10_1002_14651858_CD013107_pub2
crossref_primary_10_4178_epih_e2014019
crossref_primary_10_1186_s13643_019_0957_0
crossref_primary_10_1016_j_jclinepi_2015_03_008
crossref_primary_10_1002_14651858_CD011039
crossref_primary_10_1002_14651858_CD011037
crossref_primary_10_1002_14651858_CD013214
crossref_primary_10_1002_14651858_CD009058_pub2
crossref_primary_10_1002_14651858_CD009058_pub3
crossref_primary_10_1002_14651858_CD010164_pub2
crossref_primary_10_1186_s13643_019_1233_z
crossref_primary_10_1002_14651858_CD012123
crossref_primary_10_1002_14651858_CD012244
crossref_primary_10_1016_j_jclinepi_2020_06_025
crossref_primary_10_1002_14651858_CD011659_pub2
crossref_primary_10_1002_14651858_CD013156_pub2
crossref_primary_10_1080_21641846_2020_1848262
crossref_primary_10_1002_14651858_CD011711_pub2
crossref_primary_10_1016_S1877_1203_21_00097_5
crossref_primary_10_1371_journal_pone_0141588
crossref_primary_10_1002_14651858_CD014637
crossref_primary_10_1002_14651858_CD013545
crossref_primary_10_1177_1457496918812208
crossref_primary_10_1002_14651858_CD011639_pub2
crossref_primary_10_1002_14651858_CD007049_pub2
crossref_primary_10_1002_14651858_CD014636
crossref_primary_10_1111_add_15056
crossref_primary_10_1016_j_joen_2019_10_016
crossref_primary_10_1002_14651858_CD013301
crossref_primary_10_1177_13591053211059391
crossref_primary_10_1002_14651858_CD011002
crossref_primary_10_1002_14651858_CD012694
crossref_primary_10_1002_14651858_CD011451_pub2
crossref_primary_10_1016_j_ijnurstu_2020_103846
crossref_primary_10_1016_j_jclinepi_2016_04_005
crossref_primary_10_1097_AJP_0000000000000265
crossref_primary_10_1002_epi4_12644
crossref_primary_10_1002_jrsm_1700
crossref_primary_10_1002_14651858_CD007109_pub2
crossref_primary_10_1002_14651858_CD011510_pub2
crossref_primary_10_1002_14651858_CD013090_pub2
crossref_primary_10_1002_14651858_CD014764
crossref_primary_10_1186_s13643_021_01692_8
crossref_primary_10_3389_fphar_2024_1288479
crossref_primary_10_1002_14651858_CD013431
crossref_primary_10_1002_14651858_CD010253_pub2
crossref_primary_10_1002_14651858_CD011564_pub3
crossref_primary_10_1136_ard_2024_226129
crossref_primary_10_1002_14651858_CD011564_pub2
crossref_primary_10_1002_14651858_CD013114_pub2
crossref_primary_10_1002_14651858_CD014869_pub2
crossref_primary_10_1002_14651858_CD013646
crossref_primary_10_1016_j_watres_2014_11_033
crossref_primary_10_1002_14651858_CD006004_pub4
crossref_primary_10_1007_s10151_017_1585_0
crossref_primary_10_1371_journal_pone_0088008
crossref_primary_10_1002_14651858_CD005441_pub3
crossref_primary_10_1002_14651858_CD012481_pub2
crossref_primary_10_1186_2046_4053_3_14
crossref_primary_10_1038_s41598_022_24447_4
crossref_primary_10_1186_s13063_015_0975_8
crossref_primary_10_1002_14651858_CD011585_pub2
crossref_primary_10_1007_s40279_024_02158_2
crossref_primary_10_1016_j_jclinepi_2023_11_001
crossref_primary_10_1002_14651858_CD010507_pub2
crossref_primary_10_1002_14651858_CD014869
crossref_primary_10_1002_14651858_CD013532
crossref_primary_10_1002_14651858_CD013653
crossref_primary_10_1002_14651858_CD011233
crossref_primary_10_1186_2046_4053_3_23
crossref_primary_10_1002_14651858_CD006798_pub4
crossref_primary_10_1002_14651858_CD013089_pub2
crossref_primary_10_1016_j_jclinepi_2018_04_017
crossref_primary_10_1002_14651858_CD011506_pub2
crossref_primary_10_1016_j_jclinepi_2018_04_016
crossref_primary_10_1093_aje_kwx344
crossref_primary_10_1002_jrsm_1614
crossref_primary_10_1002_14651858_CD012897
crossref_primary_10_1002_14651858_CD013502
crossref_primary_10_1002_14651858_CD011564
crossref_primary_10_1002_14651858_CD012411
crossref_primary_10_1002_14651858_CD013500
crossref_primary_10_1002_14651858_CD013749
crossref_primary_10_1111_ijn_12948
crossref_primary_10_1002_14651858_CD011568
crossref_primary_10_1186_s13643_018_0838_y
crossref_primary_10_1002_14651858_CD011561
crossref_primary_10_1111_add_14969
crossref_primary_10_1002_14651858_CD013157_pub2
crossref_primary_10_1016_j_ctrv_2017_03_012
crossref_primary_10_1111_aas_13513
crossref_primary_10_1002_jrsm_1620
crossref_primary_10_1002_14651858_CD009497_pub3
crossref_primary_10_1002_14651858_CD009497_pub2
crossref_primary_10_1001_jamainternmed_2019_1501
crossref_primary_10_1002_14651858_CD013997
crossref_primary_10_1002_14651858_CD011313_pub2
crossref_primary_10_1002_14651858_CD011313_pub3
crossref_primary_10_1002_14651858_CD011660_pub2
crossref_primary_10_1002_14651858_CD001277_pub3
crossref_primary_10_1002_14651858_CD011573
crossref_primary_10_1002_14651858_CD010683_pub3
crossref_primary_10_1002_14651858_CD011451
crossref_primary_10_1002_14651858_CD011017_pub2
crossref_primary_10_1002_14651858_CD013106_pub2
crossref_primary_10_1186_s13049_025_01334_1
crossref_primary_10_1002_14651858_CD011645_pub2
crossref_primary_10_1007_s10151_017_1583_2
crossref_primary_10_1002_14651858_CD012758
crossref_primary_10_1002_14651858_CD012757
crossref_primary_10_1016_j_msksp_2021_102426
crossref_primary_10_1053_j_ajkd_2019_10_004
crossref_primary_10_1002_14651858_CD006574_pub4
crossref_primary_10_1002_14651858_CD012069_pub2
crossref_primary_10_1016_j_jclinepi_2017_11_026
crossref_primary_10_1002_14651858_CD010587
crossref_primary_10_1002_14651858_CD010588
crossref_primary_10_1002_14651858_CD012400
crossref_primary_10_1002_14651858_CD013731
crossref_primary_10_1016_j_bja_2024_05_033
crossref_primary_10_3724_zdxbyxb_2023_0072
crossref_primary_10_1002_14651858_CD014944
crossref_primary_10_1002_14651858_CD007337_pub4
crossref_primary_10_1002_14651858_CD007337_pub3
crossref_primary_10_1002_14651858_CD007606_pub4
crossref_primary_10_1002_14651858_CD012956_pub2
crossref_primary_10_1002_14651858_CD007606_pub3
crossref_primary_10_1016_j_ejim_2016_03_020
crossref_primary_10_1016_j_jclinepi_2017_11_025
crossref_primary_10_1155_2020_4308380
crossref_primary_10_1016_j_maturitas_2015_11_013
crossref_primary_10_1002_14651858_CD011643
crossref_primary_10_1002_14651858_CD011641
crossref_primary_10_1080_17434440_2022_2039623
crossref_primary_10_1002_14651858_CD011769
crossref_primary_10_1002_14651858_CD012971
crossref_primary_10_1002_14651858_CD004547_pub2
crossref_primary_10_1016_j_imr_2024_101043
crossref_primary_10_1002_jrsm_1543
crossref_primary_10_1016_j_jid_2018_11_019
crossref_primary_10_1002_14651858_CD006006_pub3
crossref_primary_10_1136_openhrt_2020_001288
crossref_primary_10_1186_s12874_019_0804_y
crossref_primary_10_1002_14651858_CD008716_pub3
crossref_primary_10_1002_14651858_CD012358_pub2
crossref_primary_10_1002_14651858_CD011659
crossref_primary_10_1002_14651858_CD011803_pub2
crossref_primary_10_1186_s13063_018_3136_z
crossref_primary_10_1016_j_jclinepi_2016_02_001
crossref_primary_10_1016_j_nbd_2013_10_014
crossref_primary_10_1111_aas_14316
crossref_primary_10_1186_s12888_019_2048_0
crossref_primary_10_1002_14651858_CD005640_pub3
crossref_primary_10_1111_opo_12394
crossref_primary_10_1002_14651858_CD011598_pub2
crossref_primary_10_1080_17512433_2021_1933434
crossref_primary_10_1002_14651858_CD011746
crossref_primary_10_1002_14651858_CD012956
crossref_primary_10_1002_14651858_CD010897
crossref_primary_10_1002_14651858_CD012955
crossref_primary_10_1111_phn_12240
crossref_primary_10_3389_fvets_2023_1137781
crossref_primary_10_1002_14651858_CD011981
crossref_primary_10_1016_j_jelekin_2022_102657
crossref_primary_10_3390_w10060744
crossref_primary_10_1002_14651858_CD001511_pub2
crossref_primary_10_1002_14651858_CD001511_pub3
crossref_primary_10_1002_14651858_CD001511_pub4
crossref_primary_10_47924_neurotarget2022124
crossref_primary_10_1002_14651858_CD008143_pub4
crossref_primary_10_1002_14651858_CD004792_pub5
crossref_primary_10_1002_14651858_CD008261_pub2
crossref_primary_10_1371_journal_pone_0159267
crossref_primary_10_1002_14651858_CD012608
crossref_primary_10_1002_14651858_CD002798_pub3
crossref_primary_10_1002_14651858_CD002798_pub4
crossref_primary_10_1089_tmj_2024_0050
crossref_primary_10_1371_journal_pone_0194027
crossref_primary_10_1002_14651858_CD010545
crossref_primary_10_1002_14651858_CD010546
crossref_primary_10_1002_14651858_CD009498_pub3
crossref_primary_10_1002_14651858_CD009498_pub4
crossref_primary_10_1002_14651858_CD006007_pub4
crossref_primary_10_1002_14651858_CD011717_pub2
crossref_primary_10_1002_14651858_CD008623_pub2
crossref_primary_10_1002_14651858_CD011650_pub2
crossref_primary_10_1002_14651858_CD011727
crossref_primary_10_1002_cl2_1027
crossref_primary_10_54846_jshap_1313
crossref_primary_10_1002_14651858_CD010872
crossref_primary_10_1002_14651858_CD012814
crossref_primary_10_1177_0193841X221116721
crossref_primary_10_1016_j_apmr_2014_10_026
crossref_primary_10_1002_14651858_CD012123_pub2
crossref_primary_10_1111_tmi_12330
crossref_primary_10_1002_14651858_CD010340_pub2
crossref_primary_10_1002_hec_3474
crossref_primary_10_1097_MCC_0000000000000618
crossref_primary_10_1016_j_jclinepi_2020_03_024
crossref_primary_10_1111_aas_13358
crossref_primary_10_1002_14651858_CD010163_pub3
crossref_primary_10_1002_14651858_CD011973
crossref_primary_10_1002_14651858_CD010163_pub2
crossref_primary_10_1186_s12891_016_1271_9
crossref_primary_10_1002_14651858_CD010478_pub2
crossref_primary_10_1002_14651858_CD010125_pub2
crossref_primary_10_1186_2046_4053_3_81
crossref_primary_10_1016_j_clnesp_2019_05_002
crossref_primary_10_3310_pgfar04070
crossref_primary_10_1186_2046_4053_3_89
crossref_primary_10_1002_14651858_CD011949
crossref_primary_10_1186_s12916_022_02540_9
crossref_primary_10_1186_s13643_023_02307_0
crossref_primary_10_1002_14651858_CD013122_pub2
crossref_primary_10_1002_14651858_CD012955_pub2
crossref_primary_10_1111_jcpe_12394
crossref_primary_10_1002_14651858_CD012673_pub2
crossref_primary_10_1186_s13643_023_02308_z
crossref_primary_10_1016_j_jad_2015_03_042
crossref_primary_10_1002_14651858_CD012143_pub3
crossref_primary_10_1002_14651858_CD012143_pub2
crossref_primary_10_1002_14651858_CD006660_pub3
crossref_primary_10_1542_peds_2018_3390
crossref_primary_10_1111_aas_13313
crossref_primary_10_1002_14651858_CD010252_pub2
crossref_primary_10_1002_14651858_CD010507
crossref_primary_10_1002_14651858_CD011717
crossref_primary_10_1002_14651858_CD011746_pub2
crossref_primary_10_1002_14651858_CD006930_pub3
crossref_primary_10_1002_14651858_CD010505
crossref_primary_10_1002_14651858_CD012805
crossref_primary_10_1002_14651858_CD010506
crossref_primary_10_1016_j_burns_2017_08_009
crossref_primary_10_1002_14651858_CD010504
crossref_primary_10_1007_s00423_013_1136_8
crossref_primary_10_21307_sjcapp_2018_003
crossref_primary_10_1016_j_jclinepi_2014_06_001
crossref_primary_10_1111_aos_15160
crossref_primary_10_1177_15245004241230310
crossref_primary_10_1002_14651858_CD013155_pub2
crossref_primary_10_1002_14651858_CD011314_pub2
crossref_primary_10_1007_s00134_013_2947_3
crossref_primary_10_1002_14651858_CD009004_pub2
crossref_primary_10_1002_14651858_CD010838
crossref_primary_10_1179_1465313314Y_0000000110
crossref_primary_10_1002_14651858_CD011803
crossref_primary_10_1002_14651858_CD007088_pub2
crossref_primary_10_1111_aas_13329
crossref_primary_10_1002_14651858_CD012345_pub3
crossref_primary_10_1002_14651858_CD012345_pub2
crossref_primary_10_1002_14651858_CD008884_pub2
crossref_primary_10_1016_j_ajem_2019_03_038
crossref_primary_10_1016_j_jcrc_2018_09_031
crossref_primary_10_1002_14651858_CD011573_pub2
crossref_primary_10_1002_14651858_CD004039_pub2
crossref_primary_10_1016_j_jclinepi_2015_08_027
crossref_primary_10_1002_14651858_CD011343_pub2
crossref_primary_10_1007_s11916_024_01298_4
crossref_primary_10_1002_14651858_CD011649_pub2
crossref_primary_10_1016_j_joim_2024_04_003
crossref_primary_10_1002_14651858_CD013121_pub2
crossref_primary_10_1002_14651858_CD001023_pub2
crossref_primary_10_1002_14651858_CD001023_pub3
crossref_primary_10_1186_s12888_016_1173_2
crossref_primary_10_1186_s13063_021_05759_8
crossref_primary_10_1080_08870446_2014_960653
crossref_primary_10_1002_14651858_CD010297_pub2
crossref_primary_10_1002_14651858_CD010297_pub3
crossref_primary_10_1002_14651858_CD011737_pub3
crossref_primary_10_1002_14651858_CD006803_pub4
crossref_primary_10_1002_14651858_CD011737_pub2
crossref_primary_10_1002_14651858_CD015059
crossref_primary_10_1002_14651858_CD015173
crossref_primary_10_1016_j_clnu_2022_11_015
crossref_primary_10_1002_14651858_CD003047_pub3
crossref_primary_10_1016_j_clnu_2021_05_025
crossref_primary_10_1002_14651858_CD006804_pub3
crossref_primary_10_1002_jrsm_1392
crossref_primary_10_1002_14651858_CD012334_pub2
crossref_primary_10_1016_j_jclinepi_2013_09_004
crossref_primary_10_1002_14651858_CD009885_pub3
crossref_primary_10_1002_14651858_CD013086
crossref_primary_10_1111_aas_13072
crossref_primary_10_1002_14651858_CD009885_pub2
crossref_primary_10_1002_14651858_CD013089
crossref_primary_10_1016_j_ajog_2022_04_023
crossref_primary_10_1002_14651858_CD013081
crossref_primary_10_1016_j_jclinepi_2016_07_003
crossref_primary_10_1038_s44221_023_00121_5
crossref_primary_10_3233_WOR_203174
crossref_primary_10_1016_j_jclinepi_2021_07_002
crossref_primary_10_1002_14651858_CD003177_pub5
crossref_primary_10_1002_14651858_CD003177_pub3
crossref_primary_10_1002_14651858_CD003177_pub4
crossref_primary_10_1002_14651858_CD013090
crossref_primary_10_1002_14651858_CD011648_pub2
crossref_primary_10_1002_14651858_CD012814_pub2
crossref_primary_10_1016_j_heliyon_2023_e21927
crossref_primary_10_1002_sim_7491
crossref_primary_10_1093_postmj_qgad130
crossref_primary_10_1002_14651858_CD002102_pub3
crossref_primary_10_1002_14651858_CD009182_pub2
crossref_primary_10_1177_1359105321990810
crossref_primary_10_1159_000444243
crossref_primary_10_1002_14651858_CD014278
crossref_primary_10_1016_j_jclinepi_2014_04_002
crossref_primary_10_1002_14651858_CD010277_pub2
crossref_primary_10_1002_14651858_CD010277_pub3
crossref_primary_10_1038_s41562_024_01940_6
crossref_primary_10_1002_14651858_CD013060
crossref_primary_10_1111_apt_12803
crossref_primary_10_1002_14651858_CD011197_pub3
crossref_primary_10_1002_14651858_CD011197_pub2
crossref_primary_10_1016_j_apmr_2018_12_036
crossref_primary_10_1186_s12874_016_0287_z
crossref_primary_10_1002_14651858_CD006575_pub3
crossref_primary_10_1002_14651858_CD013197
crossref_primary_10_1053_j_jvca_2013_01_004
crossref_primary_10_1186_s13643_017_0449_z
crossref_primary_10_1016_j_jclinepi_2020_05_009
crossref_primary_10_1016_j_jamda_2015_07_010
crossref_primary_10_1002_14651858_CD010903_pub2
crossref_primary_10_1161_JAHA_119_014890
crossref_primary_10_3389_fpubh_2024_1414070
crossref_primary_10_1002_14651858_CD011561_pub2
crossref_primary_10_1371_journal_pone_0107057
crossref_primary_10_1002_14651858_CD013653_pub2
crossref_primary_10_1002_14651858_CD007469_pub2
crossref_primary_10_1002_14651858_CD014497
crossref_primary_10_1016_j_amepre_2016_06_008
crossref_primary_10_1002_14651858_CD013123_pub2
crossref_primary_10_1002_14651858_CD013289
crossref_primary_10_1371_journal_pone_0074558
crossref_primary_10_1002_14651858_CD006390_pub2
crossref_primary_10_1002_14651858_CD014371
crossref_primary_10_1002_14651858_CD008735_pub3
crossref_primary_10_1002_14651858_CD008735_pub2
crossref_primary_10_1002_14651858_CD011094_pub3
crossref_primary_10_1002_14651858_CD010180_pub2
crossref_primary_10_1002_14651858_CD011094_pub4
crossref_primary_10_1002_14651858_CD015119
crossref_primary_10_1002_14651858_CD006573_pub3
crossref_primary_10_1002_14651858_CD013175
crossref_primary_10_1002_14651858_CD013174
crossref_primary_10_1016_j_ijid_2022_01_002
crossref_primary_10_1002_14651858_CD008717_pub2
crossref_primary_10_1002_14651858_CD008717_pub3
crossref_primary_10_1002_14651858_CD012244_pub2
crossref_primary_10_1111_jebm_12344
crossref_primary_10_1002_14651858_CD013125_pub2
crossref_primary_10_1002_14651858_CD004149_pub3
crossref_primary_10_1080_19439342_2022_2153380
crossref_primary_10_1002_da_22472
crossref_primary_10_3238_arztebl_2017_0635
crossref_primary_10_1002_14651858_CD010162_pub2
crossref_primary_10_1016_j_maturitas_2016_01_012
crossref_primary_10_1016_j_jclinepi_2023_09_001
crossref_primary_10_1111_1471_0528_12914
crossref_primary_10_1002_14651858_CD013203_pub2
crossref_primary_10_1186_s13063_016_1331_3
crossref_primary_10_1002_14651858_CD011769_pub2
crossref_primary_10_1002_14651858_CD011973_pub2
crossref_primary_10_1111_aas_14140
crossref_primary_10_1111_aas_14143
crossref_primary_10_3109_0284186X_2014_954677
crossref_primary_10_1002_14651858_CD011646_pub2
crossref_primary_10_1002_14651858_CD010546_pub2
crossref_primary_10_1016_j_ijnurstu_2014_11_008
crossref_primary_10_1002_14651858_CD009933_pub2
crossref_primary_10_1002_14651858_CD013157
crossref_primary_10_1002_14651858_CD013156
crossref_primary_10_1002_14651858_CD013155
crossref_primary_10_1186_s13643_020_01566_5
crossref_primary_10_1002_14651858_CD002149
crossref_primary_10_1177_00220345211025242
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.3310/hta16350
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2046-4924
ExternalDocumentID oai_doaj_org_article_0dc2dfabefc24740adfa31fbdf43cb2b
22989478
10_3310_hta16350
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation National Institute for Health Research Health Technology Assessment programme.
GrantInformation_xml – fundername: Medical Research Council
  grantid: G0800800
– fundername: Medical Research Council
  grantid: G0802413
– fundername: Medical Research Council
  grantid: G0701659
GroupedDBID ---
53G
5GY
AAYXX
ADBBV
ADDVE
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCNDV
CITATION
CZQ
DIK
EBS
EJD
F5P
GROUPED_DOAJ
OK1
P2P
P6G
TR2
W2D
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c383t-4d766163ab8ed6497e91f8b81909c65a9b6bfd98a8aa3f80fc2f1305756436f23
IEDL.DBID DOA
ISSN 1366-5278
2046-4924
IngestDate Wed Aug 27 01:29:38 EDT 2025
Fri Jul 11 06:43:05 EDT 2025
Sat May 31 02:14:04 EDT 2025
Tue Jul 01 01:47:54 EDT 2025
Thu Apr 24 23:12:24 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 35
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c383t-4d766163ab8ed6497e91f8b81909c65a9b6bfd98a8aa3f80fc2f1305756436f23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://doaj.org/article/0dc2dfabefc24740adfa31fbdf43cb2b
PMID 22989478
PQID 1041325827
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_0dc2dfabefc24740adfa31fbdf43cb2b
proquest_miscellaneous_1041325827
pubmed_primary_22989478
crossref_primary_10_3310_hta16350
crossref_citationtrail_10_3310_hta16350
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-09-01
PublicationDateYYYYMMDD 2012-09-01
PublicationDate_xml – month: 09
  year: 2012
  text: 2012-09-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Health technology assessment (Winchester, England)
PublicationTitleAlternate Health Technol Assess
PublicationYear 2012
Publisher NIHR Journals Library
Publisher_xml – name: NIHR Journals Library
SSID ssj0041651
Score 2.5563493
SecondaryResourceType review_article
Snippet The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants...
Background: The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
StartPage 1
SubjectTerms allocation concealment
Bias
blinding
Data Interpretation, Statistical
Databases, Bibliographic
Epidemiologic Research Design
Humans
meta-analysis
Meta-Analysis as Topic
meta-epidemiological study
Outcome Assessment, Health Care - methods
Outcome Assessment, Health Care - standards
Outcome Assessment, Health Care - statistics & numerical data
randomisation
Randomized Controlled Trials as Topic - standards
Randomized Controlled Trials as Topic - statistics & numerical data
Reproducibility of Results
Title Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies
URI https://www.ncbi.nlm.nih.gov/pubmed/22989478
https://www.proquest.com/docview/1041325827
https://doaj.org/article/0dc2dfabefc24740adfa31fbdf43cb2b
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7qQbyIb9cXEQRPxd2km6beVBQVFAQF8VImTYKC24rW_-TPdCZp1xUUL95KmjYhM81808x8w9ie0uBk30Fi00wmdLKUgDcmER5tX2ly6APlO19dq_O79PJ-eD9R6otiwiI9cFy4g74thfVgnC9FmqX4qAc58Mb6VJZGGNp90eZ1zlTcgxFlDNuMK4WuVqYj7axELHPw2ABiEMqznzBEga__d5AZjM3ZAptvUSI_irNbZFOuWmKzV-05-DL7uOhqi_Da8_jf31keuGK5DUEZvPxOxczrij9NBDjyGMnBiWVjRICTU6YJR9Nla5Q9vq2NYn_Gy1Db4-0Qm0boSWMDtFwmNPzINZC4r0qzJPYwFXTCV9jd2entyXnS1lxISvRVmyS1GVpsJcFoZ1WaZy4feG0IN-SlGkJulPE216ABpNd9lIpHM4igD6GN8kKuspmqrtw6ZYNLrayWGj_51EirrQU78EIbA0473WP7nQCKsiUkp7oYzwU6JiSqohNVj-2Oe75EEo4f-hyTDMf3iTY7NKAyFa0yFX8pEw7UaUCBS01nJ1C5-v0Nh0NrL4ZaZD22FlVjPJQILPaZ3viPKWyyOcRkIoaxbbGZ5vXdbSPuacwOmz55uNkJiv4JejwKWA
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+reported+study+design+characteristics+on+intervention+effect+estimates+from+randomised+controlled+trials%3A+combined+analysis+of+meta-epidemiological+studies&rft.jtitle=Health+technology+assessment+%28Winchester%2C+England%29&rft.au=J+Savovi%C4%87&rft.au=HE+Jones&rft.au=DG+Altman&rft.au=RJ+Harris&rft.date=2012-09-01&rft.pub=NIHR+Journals+Library&rft.issn=1366-5278&rft.eissn=2046-4924&rft.volume=16&rft.issue=35&rft_id=info:doi/10.3310%2Fhta16350&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0dc2dfabefc24740adfa31fbdf43cb2b
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1366-5278&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1366-5278&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1366-5278&client=summon